4basebio Share Discussion Threads

[pejaten] 30/7/2024 07:29

Great isn't it?

[philly cheesesteak] 30/7/2024 07:17

Am I the only one that's seen this hugely exciting news? £40m invested at a premium to a share price which has risen 112% YTD is some statement of intent

[philly cheesesteak] 30/7/2024 07:13

hxxps://polaris.brighterir.com/public/4basebio/news/rns/story/xekkqjx

"July 29, 2024 - 4basebio PLC (AIM: 4BB) ("4basebio" or the "Company"), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announces that it has agreed to binding terms with (i) Elevage Medical Technologies ("Elevage"), a Patient Square Capital platform and (ii) Prudential Assurance Company Limited acting by its investment manager M&G Investment Management Limited ("M&G"), for a combined investment of £40.0 million through an issuance (the "Issuance") of ordinary shares of €1 each at an issue price of 1,500 pence per Ordinary Share (the "Issue Price")."

Dr Heikki Lanckriet, CEO and CSO, 4basebio, said: "The evolution of the Group since its spin out at the end of 2020 has been profound. Our client base and pipeline has grown significantly as a result of strong interest in our synthetic DNA products, and we expect client acquisition and revenue generation to continue accelerating.

"The capital raise announced today will further drive the momentum of the Company, and I am pleased to see Elevage and M&G join our shareholder register."

John Marotta, Executive in Residence, Patient Square Capital, said: "This investment reflects strong conviction in synthetic DNA's potential to advance novel healthcare treatments, and its place as a significant part of the cell and gene therapy market. We are well aligned with the team at 4basebio and are eager to help them reach their next phase of growth with this investment."

M&G Portfolio Manager, Jeremy Punnett, said: "The UK has a wealth of innovative deep tech firms that are breaking the mould, but it is vital they get the long-term investment they need to become the next global champions. M&G's Crossover strategy is playing a leading role in helping businesses to scale and thrive by providing expertise and patient capital.

"We are delighted to partner with Elevage in supporting 4basebio's pioneering work in synthetic DNA, which underpins the development of cell and gene therapies and offers the potential to transform healthcare and save millions of lives. We look forward to being part of their exciting journey and contributing to the advancement of cutting-edge therapies."

[aberloon2] 14/5/2024 14:53

More news to drop? Nice rise out of the blue...

[buzzzzzzzz] 12/4/2024 12:41

RNS re Tier 1 Pharma

Good news just keeps coming.

[pob69] 21/3/2024 08:29

Here's the CEO of Helixnano on the trials;

[buzzzzzzzz] 10/3/2024 22:30

Dont I know it!!!

[chicken charlie] 09/3/2024 09:23

chicken charlie is

[buzzzzzzzz] 08/3/2024 16:58

You are right great RNS.

Are you a holder I do not check in that often as I do not think anyone else is in this?

[babbler] 01/3/2024 07:28

Looks like you will be fine. Nice rns this morning.

[buzzzzzzzz] 29/2/2024 17:09

An all time high.........Huzzah!

[buzzzzzzzz] 10/2/2024 10:22

A profit is a profit, well done!

I am in for the long haul!

Wish me luck!

[hydrus] 07/2/2024 08:03

BUzzzz - sorry for delay no I am not. Watching with interest but I exited with a good profit after a portfolio review.

[buzzzzzzzz] 02/2/2024 16:00

Todays RNS is a clear signal the company is for sale.

Question is at what price and what timeframe , CEO and CFO have a great incentive looking at the bonus stated in the RNS.

Interesting times!

[buzzzzzzzz] 13/2/2023 12:17

Zours increasing his holding through Delphi.........must be confident!

[gsbmba99] 08/2/2023 07:56

A bit of coverage for the sector.

[buzzzzzzzz] 30/9/2022 07:40

pob69

Thanks for posting!

[pob69] 30/9/2022 06:40

Finncap comment;

...results reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase in cashburn as headcount increases, near-term funding is not considered an issue, given that it can draw down from its €25m loan facility.

...minor changes to forecasts to reflect increased headcount and higher capex, with year-end cash forecast to be £1.9m (previously £2.3m). We maintain our sum-of-the-parts DCF target price of 1,200p, which is underpinned by the expected high demand for DNA/RNA and the significant potential of its technology to address key challenges in the cell and gene therapy space.

[hydrus] 09/8/2022 07:47

Good to hear Buzz. Looking forward to how this interesting company progresses over next few years.

[buzzzzzzzz] 09/8/2022 06:36

Well done Hydrus.

I went to the AGM steady progress being made.

[hydrus] 03/8/2022 11:38

Great recovery here - still holding

[buzzzzzzzz] 01/8/2022 20:31

free stock charts from uk.advfn.com

[buzzzzzzzz] 01/8/2022 20:30

Nice rise, downtrend broken!

[buzzzzzzzz] 25/7/2022 15:34

Nice to see the CFO pick up another 5,000 shares in June.

Management certainly putting their money where their mouth is!

Decent buying today pushing price back up.

[buzzzzzzzz] 23/5/2022 16:16

RNS 11th and 12th May.

Looks like they were able to buy after the results.

I will probably go to the AGM.